DCC-2036 (Rebastinib) Datasheet DC Chemicals

Description	DCC-2036 is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1/2.
Cat.No	DC5041
Name	DCC-2036 (Rebastinib)

Chemical Properties

CAS	1020172-07-9
Formula	C30H28FN7O3
MW	553.59
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

References

[1]. Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.

Return Policy

If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.

Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.

Tel: +86-21-58447131
Fax: +86-21-61642470

Email:
sales@dcchemicals.com
order@dcchemicals.com

Website:
www.dcchemicals.com